View Older Stories View More Recent Stories
-
Biogen (BIIB) PT Raised to $245 at Canaccord
-
William Blair on Biogen (BIIB): 'we see potential to add $1.54 billion in sales' through APLS deal
-
Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal
-
William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
-
Biogen (BIIB) call put ratio 1.6 calls to 1 put after acquiring Apellis (APLS)
-
Barclays on Biogen (BIIB): Apellis deal 'signals confidence' ahead of felzartamab readouts
-
Stifel on Biogen (BIIB): Apellis acquisition 'surprising,' but makes sense given move towards rare kidney
-
BMO Capital on Biogen (BIIB): Apellis deal 'sets a clear path for further expansion in nephrology'
-
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVR
-
BofA Securities on Biogen (BIIB): 'clear positive trend in execution'
-
Biogen will introduce 28 mg vial at same price as 12 mg vial, resulting in parity pricing for patients in the maintenance phase - Spokesperson
-
BMO Capital Reiterates Market Perform Rating on Biogen (BIIB)
-
Morgan Stanley Reiterates Equalweight Rating on Biogen (BIIB)
-
Jefferies Reiterates Buy Rating on Biogen (BIIB) following FDA approval of HD Spinraza for SMA
-
LEQEMBI shows high treatment persistence in real-world study
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB): "continue to view SMA as an important franchise"
-
Biogen reports positive salanersen trial results in SMA patients
-
Barclays Starts Biogen (BIIB) at Equalweight
-
Biogen names Dr. Maria Freire as new board chair
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) PT Raised to $196 at BMO Capital
-
Biogen (BIIB) PT Raised to $215 at TD Cowen
-
Biogen (BIIB) PT Raised to $233 at RBC Capital
-
Biogen (BIIB) PT Raised to $177 at Piper Sandler as 'Leqembi Continues to Ramp Well'
-
'We Are Getting More Constructive Biogen (BIIB)'; PT Raised to $201 at Bernstein
-
Biogen (BIIB) PT Raised to $230 at Canaccord Genuity
-
Biogen (BIIB) PT Raised to $246 at Guggenheim
-
Biogen (BIIB) PT Raised to $228 at H.C. Wainwright
-
Baird Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) PT Raised to $250 at Oppenheimer
-
Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong
-
Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance
-
Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus
-
Biogen (BIIB) call put ratio 12 calls to 1 put into quarter results
-
Biogen (BIIB) call put ratio 2.5 calls to 1 put into quarter results
-
Biogen (BIIB) call put ratio 1 call to 1.2 puts into quarter results
-
BIOGEN publishes study results for high-dose nusinersen in Nature Medicine
-
Biogen (BIIB) PT Lowered to $191 at Bernstein
-
JPMorgan on Biogen (BIIB) in 2026: 'Watching Pipeline Derisking Through the Year'
-
Biogen expects $222M charge from research deals in Q4 2025
-
RBC Capital on Biogen (BIIB): 'Competition from assets such as trontinemab remains years away, and not a threat this decade most likely'
-
BIOGEN receives EU approval for high dose SPINRAZA for spinal muscular atrophy
-
4Q25/2026 Biotech Earnings Preview: RBC
-
Biogen (BIIB) PT Raised to $207 at Mizuho
-
UBS Assumes Biogen (BIIB) at Neutral
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
RBC: 'We have just confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145'
-
Western Digital stock rises after inclusion in Nasdaq-100 Index
-
HSBC highlights one pharma stock to buy and one to sell for 2026
